Mezzion Pharma Co.Ltd(140410)

Description: Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

---

Keywords: Organic Compounds Chemical Compounds Hypertension Respiratory Diseases Chronic Obstructive Pulmonary Disease Vascular Disease Erectile Dysfunction Pulmonary Arterial Hypertension Benign Prostatic Hyperplasia Lactams Pulmonary Hypertension Overactive Bladder Cgmp Specific Phosphodiesterase Type 5 Heterocyclic Compounds Pde5 Inhibitors Treatment Of Vascular Diseases

---

Home Page: www.mezzion.co.kr

C&H Building
Seoul,
South Korea
Phone: 82 2 560 8000

---

Officers

Exchange: KQ

Country: KR

Currency: Korean Won (₩)